Recombinant CA9 (Girentuximab Biosimilar) antibody
Research Grade
Reactivity: Human
ELISA, WB
Host: Human, Mouse
Chimeric
unconjugated
Recombinant Antibody
-
- Target See all CA9 (Girentuximab Biosimilar) products
- CA9 (Girentuximab Biosimilar)
- Antibody Type
- Recombinant Antibody
- Reactivity
- Human
-
Host
- Human, Mouse
- Expression System
- Mammalian cells
-
Clonality
- Chimeric
-
Conjugate
- This CA9 (Girentuximab Biosimilar) antibody is un-conjugated
- Application
- ELISA, Western Blotting (WB)
- Purpose
- Girentuximab Biosimilar - Anti-CA9 mAb - Research Grade
- Characteristics
- Antibody Type: IgG1-kappa
- Purification
- Recombinant antibody expressed in mammalien cells and purified.
- Purity
- > 85%
- Grade
- Research Grade
- Isotype
- IgG1 kappa
-
anti-CA9 (Girentuximab Biosimilar) antibody
Research Grade Reactivity: Human ELISA, FACS Host: Mouse Chimeric unconjugated Recombinant Antibody
-
- Restrictions
- For Research Use only
-
- Buffer
- PBS buffer PH7.5
- Storage
- -80 °C
- Storage Comment
- store at -80°C
-
- Target
- CA9 (Girentuximab Biosimilar)
- Abstract
- CA9 (Girentuximab Biosimilar) Products
- Target Type
- Biosimilar
- Background
- Recombinant chimeric antibody binding to human CA9. Girentuximab is a chimeric monoclonal antibody designed for the treatment of renal cell carcinoma.
- CAS-No
- 916138-87-9
-
You are here:
